<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Burns Trauma</journal-id><journal-id journal-id-type="iso-abbrev">Burns Trauma</journal-id><journal-title-group><journal-title>Burns &#x00026; Trauma</journal-title></journal-title-group><issn pub-type="ppub">2321-3868</issn><issn pub-type="epub">2321-3876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31497611</article-id><article-id pub-id-type="pmc">6717987</article-id><article-id pub-id-type="publisher-id">161</article-id><article-id pub-id-type="doi">10.1186/s41038-019-0161-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Acute surgical vs non-surgical management for ocular and peri-ocular burns:&#x000a0;a&#x000a0;systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2742-4319</contrib-id><name><surname>Klifto</surname><given-names>Kevin M.</given-names></name><address><phone>1-410-550-0886</phone><email>kklifto@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Elhelali</surname><given-names>Ala</given-names></name><address><email>aelhela1@jhmi.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gurno</surname><given-names>Caresse F.</given-names></name><address><email>chollen4@jhmi.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Seal</surname><given-names>Stella M.</given-names></name><address><email>sms@jhmi.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Asif</surname><given-names>Mohammed</given-names></name><address><email>masif2@jhmi.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hultman</surname><given-names>C. Scott</given-names></name><address><email>chultma1@jhmi.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>Department of Plastic and Reconstructive Surgery, </institution><institution>The Johns Hopkins University School of Medicine, </institution></institution-wrap>Baltimore, MD USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>The Johns Hopkins University School of Nursing, </institution></institution-wrap>Baltimore, MD USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>Welch Medical Library, </institution><institution>The Johns Hopkins University School of Medicine, </institution></institution-wrap>Baltimore, MD USA </aff><aff id="Aff4"><label>4</label>The Johns Hopkins Burn Center, 4940 Eastern Avenue, Baltimore, MD 21224 USA </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>7</volume><elocation-id>25</elocation-id><history><date date-type="received"><day>22</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Burn-related injury to the face involving the structures of the eyes, eyelids, eyelashes, and/or eyebrows could result in multiple reconstructive procedures to improve functional and cosmetic outcomes, and correct complications following poor acute phase management. The objective of this article was to evaluate if non-surgical or surgical interventions are best for acute management of ocular and/or peri-ocular burns.</p></sec><sec><title>Methods</title><p id="Par2">This systematic review and meta-analysis compared 272 surgical to 535 non-surgical interventions within 1&#x000a0;month of patients suffering burn-related injuries to 465 eyes, 253 eyelids, 90 eyelashes, and 0 eyebrows and evaluated associated outcomes and complications. The PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases were systematically and independently searched. Patient and clinical characteristics, surgical and medical interventions, outcomes, and complications were recorded.</p></sec><sec><title>Results</title><p id="Par3">Eight of the 14,927 studies queried for this study were eligible for the systematic review and meta-analysis, with results from 33 of the possible 58 outcomes and complications using Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) and Cochrane guidelines. Surgery was associated with standard mean differences (SMD) 0.44 greater visual acuity on follow-up, SMD 1.63&#x02009;mm shorter epithelial defect diameters on follow-up, SMD 1.55&#x02009;mm greater changes in epithelial diameters from baseline, SMD 1.17&#x000a0;mm<sup>2</sup> smaller epithelial defect areas on follow-up, SMD 1.37&#x000a0;mm<sup>2</sup> greater changes in epithelial defect areas from baseline, risk ratios (RR) 1.22 greater numbers of healed epithelial defects, RR 11.17 more keratitis infections, and a 2.2 greater reduction in limbal ischemia compared to no surgical intervention.</p></sec><sec><title>Conclusions</title><p id="Par4">This systematic review and meta-analysis found that compared to non-surgical interventions, acute surgical interventions for ocular, eyelid, and/or eyelash burns were found to have greater visual acuity on follow-up, shorter epithelial defect diameters on follow-up, greater changes in epithelial diameters from baseline, smaller epithelial defect areas on follow-up, greater changes in epithelial defect areas from baseline, greater numbers of healed epithelial defects, more keratitis infections, and a greater reduction in limbal ischemia, possibility preventing the need of a future limbal stem cell transplantation.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s41038-019-0161-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Burns</kwd><kwd>Eyelashes</kwd><kwd>Eyebrows</kwd><kwd>Eye</kwd><kwd>Visual acuity</kwd><kwd>Keratitis</kwd><kwd>Stem cell transplantation</kwd><kwd>Ocular</kwd><kwd>Peri-ocular</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par21">Burn-related injury to the face involving the structures of the eyes, eyelids, eyelashes, and/or eyebrows could result in multiple reconstructive procedures to improve functional and cosmetic outcomes, and correct complications following poor acute phase management. Burn injury to ocular structures requires patient transfer to specialized burn centers, where early evaluation by an oculoplastic surgeon may prevent long-term morbidity [<xref ref-type="bibr" rid="CR1">1</xref>]. The majority of ocular burns do not require surgical interventions, and rates of long-term morbidity have been reported as low as 4.5% with medical management alone [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Prior associated risk factors identified for surgical interventions after ocular burns have been deep eyelid burns, flame burns, increasing severity of corneal injuries, periorbital edema, visual loss on presentation, and keratitis [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par22">This review provides healthcare providers with insight on outcomes and complications in burn-related injury to the eyes, eyelids, eyelashes, and eyebrows. Surgeons may be more or less likely to perform surgical procedures if they can determine when they are most necessary. Patients can be informed early of realistic expectations following surgical or medical management alone when consenting to treatment.</p><p id="Par23">This new systematic review and meta-analysis compared surgical to non-surgical interventions within 1&#x000a0;month of patients suffering burn-related injuries to the eyes, eyelids, eyelashes, and/or eyebrows. Based on peer-reviewed literature, it was hypothesized that early surgical interventions for severe burn-related injury to the eye, eyelid, eyelash, and/or eyebrow would result in better patient-related outcomes and lower risks of complications, compared to non-surgical interventions alone.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par24">Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines were followed throughout the literature search process to structure the framework for the review [<xref ref-type="bibr" rid="CR5">5</xref>].</p><sec id="Sec3"><title>Selection criteria</title><p id="Par25">The participants, interventions, comparisons, outcomes, and study design (PICOS) strategy was followed for inclusion throughout the selection process. Participants were of a mean age &#x02265;&#x02009;15&#x02009;years for each study, treated as either inpatients or outpatients, and suffered burn-related injury (thermal, scald, contact, electrical, chemical), to the anatomical subunit of the eye, eyelid, eyelash, and/or eyebrow. Interventions were either surgical (direct closure, split-thickness graft, full-thickness graft, skin substitute, tissue flap, tarsorrhaphy, amniotic membrane transplant (AMT), conjunctival limbal autograft transplantation (CLAT), keratolimbal allograft transplantation, deep anterior lamellar keratoplasty (DALK), and/or penetrating keratoplasty) or non-surgical conventional medical therapy alone (topical lubricants/irrigation, topical antimicrobial, topical anti-glaucoma, oral medication, oral antimicrobial, oral anti-glaucoma, pressure garment) intended for direct care of the ocular, eyelid, eyelash, and/or eyebrow burn within 1&#x000a0;month of the injury (acute). Comparisons were made between the two intervention groups. Burn patients in the surgical group were compared to the non-surgical group by the ocular, eyelid, eyelash, and/or eyebrow anatomical subunits of the face involved in the burn injury (surgical eyelid compared to non-surgical eyelid). Outcomes measured were burn etiologies; time to burn management in days; percent total body surface area (%TBSA) burned; depth of burn of eyelid, eyelash, and eyebrow (superficial (S), superficial partial thickness (SPT), deep partial thickness (DPT), full thickness (FT)); severity of ocular burn by Dua&#x02019;s classification [<xref ref-type="bibr" rid="CR6">6</xref>] (Grades I&#x02013;VI) or Roper-Hall classification [<xref ref-type="bibr" rid="CR7">7</xref>] (Grades I&#x02013;IV) for corneal or conjunctival involvement; visual acuity measured by Snellen charts and expressed in decimals or logarithm of minimum angle of resolution (logMAR); change in visual acuity, corneal clarity, corneal haze, change in corneal haze, corneal epithelial defect diameter (mm), change in corneal epithelial defect diameter, epithelial defect area (mm<sup>2</sup>), change in epithelial defect area, time to epithelialization, and healed epithelial defects by slit-lamp examination and fluorescein staining; pain scale severity measurement graded 0&#x02013;10; change in pain scale severity score; tear film status measured by tear break-up time (TBUT)&#x000a0;in seconds and Schirmer test; limbal ischemia measured in clock hours; hospital length of stay (LOS) in days; inhalation injury; rate of intubation and mechanical ventilation; number of days on a ventilator; intensive care unit (ICU) LOS in days; need for reconstruction; time to reconstruction; and mortality. Complications measured were wound/ocular infection, keloid/hypertrophic scar, eyelid contracture, eyelid ectopian, eyelid entropian, corneal ulceration, corneal vascularization, vision loss, neurovascular bundle compression, symblepharon, and ocular perforation. All outcomes and complications were measured at initial evaluation and at a designated follow-up. Study designs considered were randomized controlled trials (RCTs), clustered RCTs, non-RCTs, retrospective studies, observational studies, prospective studies, case-control studies, and cohort studies. There was no predetermined length of follow-up for participants or specific years considered for publication status. Studies excluded are as follows: if they were not in English, were systematic reviews or review articles with no contribution of new data, non-reviewed peer literature, cadaver studies, animal studies, case-reports, editorial articles, if the full-article was unavailable, patient death occurred prior to evaluation, studies not related to any of the outcomes or complications analyzed, studies with no comparison between surgical and non-surgical interventions, interventions were not performed during the designated acute management time period, involved chronic reconstruction methods, and studies with less than a sample size of 10 in each intervention group to perform the meta-analysis.</p></sec><sec id="Sec4"><title>Search</title><p id="Par26">A medical library informationist (SMS) conducted the initial literature search using five databases (MEDLINE via PubMed, Embase, Cochrane, Web of Science, and Scopus) from inception to January 18, 2019 (Additional&#x000a0;file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref> for search strategy). Reference lists of relevant articles were hand searched to identify additional relevant studies. All references were imported into Covidence (Veritas Health Innovation Ltd., Melbourne, Australia), and reference management software and duplicates were removed.</p></sec><sec id="Sec5"><title>Data extraction</title><p id="Par27">Two reviewers (KMK and AE) systematically and independently performed the title/abstract screening, followed by full-article review to ensure quality and accuracy throughout the process. Any disagreements regarding studies included or excluded were resolved by discussion. If disagreements were still present after discussion, a third reviewer (CSH) resolved remaining conflict. The following data were extracted qualitatively and quantitatively for outcome and complication variables of interest: authors, year of publication, type of study, sample size, male and female distributions, age, location of burn, time to burn management, burn etiology (thermal, scald, contact, electrical, chemical: acid, alkali, or uncategorized), direct closure, split-thickness graft, full-thickness graft, skin substitute, tissue flap, tarsorrhaphy, AMT, CLAT, keratolimbal allograft transplantation, DALK, penetrating keratoplasty, topical lubricants/irrigation, topical antimicrobial, topical anti-glaucoma, oral medication, oral antimicrobial, oral anti-glaucoma, pressure garment, %TBSA, depth of burn of eyelid, severity of ocular burn by Dua&#x02019;s Grades I-VI, Roper-Hall Grades I-IV, visual acuity in decimals or logMAR, corneal clarity, corneal haze, corneal epithelial defect diameter, epithelial defect area, time to epithelialization, number of healed epithelial defects, pain scale severity measurements, TBUT, Schirmer test, limbal ischemia, hospital LOS, inhalation injury, rate of intubation and mechanical ventilation, number of days on a ventilator, ICU LOS, need for reconstruction, time to reconstruction, mortality, wound/ocular infection, keloid/hypertrophic scar, eyelid contracture, eyelid ectopian, eyelid entropian, corneal ulceration, corneal vascularization, vision loss, neurovascular bundle compression, symblepharon, and ocular perforation. If there were multiple reports from the same study, one data collection form was completed for the study from all of the reports to avoid duplicating results.</p></sec><sec id="Sec6"><title>Quality assessment</title><p id="Par28">Two reviewers (KMK and CFG) assessed the risk of bias individually for each study at a study level. This was followed by an assessment across all studies in the meta-analysis using the Cochrane risk of bias tool [<xref ref-type="bibr" rid="CR8">8</xref>]. Both parts of the Cochrane risk of bias tool were used. The first part was categorized in terms of low, high, or unclear risk. The second part used the quality of evidence GRADE and was categorized in terms of high, moderate, low, and very low quality of evidence. Randomized studies were assessed for the seven risks of bias domains. Non-randomized studies were assessed for baseline patient characteristics, adjustments for confounding variables, and classifications of interventions. Outcomes and complications from different studies were compared at the same time intervals on follow-up. All studies available meeting criteria were included in data synthesis.</p></sec><sec id="Sec7"><title>Unit of analysis issues</title><p id="Par29">When a study reported patients with ocular, eyelid, eyelash, and/or eyebrow burns, each anatomical subunit was totaled and reported on an individual basis (assessed eyes, not patients). We extracted data in the form the authors reported. If raw data was unavailable and two different populations were compared in a single study for the same group, those groups were separated as two different studies as long as a minimum of ten eyes/eyelids/eyelashes/eyebrows were available to perform the meta-analysis (author: surgical and non-surgical treatment for ocular burns Dua&#x02019;s Grade II and grade III; author: surgical and non-surgical treatment for ocular burns Dua&#x02019;s Grade II, author: surgical and non-surgical treatment for ocular burns Dua&#x02019;s Grade III). When less than ten eyes/eyelids/eyelashes were categorized into different severities of grades, scores were combined into one group for analysis (Dua&#x02019;s Grade III, <italic>n</italic>&#x02009;=&#x02009;6 and Dua&#x02019;s Grade IV, <italic>n</italic>&#x02009;=&#x02009;6 receiving AMT, <italic>n</italic>&#x02009;=&#x02009;12 Dua&#x02019;s Grade III/IV receiving AMT). If studies reported multiple anatomical subunits but the sample size was unclear as to which subunit it pertained, the largest identifiable sample was used. Values were not combined to avoid duplicating samples (three cases of eyelid ectropian reported in a sample size involving burns to 30 eyes and 20 eyelids, 3/30 occurrences of eyelid ectropian). Outcomes and complications subdivided by individual grades were combined or averaged from respective studies into one value for appropriate comparison based on dichotomous or continuous data, respectively. Visual acuity expressed as logMAR was converted to a decimal using a standard conversion table [<xref ref-type="bibr" rid="CR9">9</xref>]. Corneal clarity or transparency was converted to corneal haze [<xref ref-type="bibr" rid="CR10">10</xref>]. Roper-Hall classified burns were converted to Dua&#x02019;s classified burns to standardize comparisons between studies. Roper-Hall Grade IV burns were converted to Dua&#x02019;s Grade IV/V/VI burns [<xref ref-type="bibr" rid="CR10">10</xref>]. Severity pain scale measurements were converted to the 0&#x02013;10 scale across all studies that reported pain. Outcomes were compared at the same follow-up time for all studies. If intervals differed between studies, they were analyzed using descriptive statistics and stated in the review.</p></sec><sec id="Sec8"><title>Data synthesis and statistical analysis</title><p id="Par30">A summary of findings table was created for seven outcomes of interest using GRADEproGDT software (Evidence Prime Inc., McMaster University, 2015) to include the number of eyes, eyelids, and/or eyelashes, studies for each outcome and complication, the magnitude of effect, and measurement of the quality of evidence. Medians, interquartile ranges, and ranges were converted to means and standard deviations for studies that did not provide the appropriate data [<xref ref-type="bibr" rid="CR11">11</xref>]. Summary data estimates were converted to risk ratios (RR) to allow proper data comparison and interpretation using the formula and recommendations in the Cochrane Handbook [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The RevMan software, Version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen) was used to perform the meta-analysis. Descriptive statistics were applied to quantify burn severities, different surgical procedures, medications, unequal follow-up times, and any value less than 10 to perform the meta-analysis. Due to the discrepancy in measurements, converting variables in studies to a comparable unit, averaging overall grades within studies, different burn etiologies, different surgical procedures, and demographic characteristics, the random effects model was used in all meta-analysis outcomes and complications [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. RRs with 95% confidence intervals (CIs) were used for dichotomous outcomes and complications. Standard mean differences (SMD) with 95% CI were used for continuous outcomes and complications due to variations in studies.</p><p id="Par31">Study heterogeneity was measured using <italic>I</italic><sup>2</sup>. Heterogeneity was examined by inspection of forest plots and tested with chi<sup>2</sup> to determine what percentage of variability was not due to sampling error. <italic>I</italic><sup>2</sup> values &#x0003c;&#x02009;50% were low, medium 50&#x02013;75%, and high &#x0003e;&#x02009;75% [<xref ref-type="bibr" rid="CR14">14</xref>]. If significant heterogeneity was present, we included a structured description and summary of the findings of included studies in the review. Sensitivity analysis using the single study elimination method was used to identify which study contributed to the highest level of heterogeneity. All meta-analysis outcomes were two-tailed, with a significance level set at <italic>&#x003b1;</italic> of 0.05. No additional analyses were performed during our study.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Study selection and characteristics</title><p id="Par32">The search resulted in 14,927 citations; after removing 6469 duplicates, 8458 unique citations remained. Following title/abstract review, 7924 articles were excluded and 534 articles were eligible for full-text review. Following full-text review, 8 articles were eligible and included in the systematic review (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. All 8 articles were eligible for final data extraction and meta-analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of ocular and peri-ocular burns&#x000a0;studies included in systematic review and meta-analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Author</th><th>Year</th><th>Design</th><th>Sample size</th><th>Etiology</th><th>Group characteristics</th><th>Burn classification</th><th>Outcomes</th><th>Complications</th></tr></thead><tbody><tr><td>Frank et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>1983</td><td>Retrospective cohort</td><td>92</td><td>&#x02022; &#x02013;</td><td><p>&#x02022; Eyelid surgery</p><p>&#x02022; Eyelid no surgery</p></td><td><p>&#x02022; DPT</p><p>&#x02022; FT</p></td><td>&#x02022; &#x02013;</td><td><p>&#x02022; Corneal ulceration</p><p>&#x02022; Vision loss</p><p>&#x02022; Ectropian</p><p>&#x02022; Eye perforation</p></td></tr><tr><td>Tamhane et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td>2005</td><td>Prospective, randomized trial</td><td>44</td><td><p>&#x02022; Thermal</p><p>&#x02022; Acid</p><p>&#x02022; Alkali</p></td><td><p>&#x02022; Eye surgery</p><p>&#x02022; Eye no surgery</p></td><td>&#x02022; Dua&#x02019;s grade II-VI</td><td><p>&#x02022; Visual acuity</p><p>&#x02022; Pain</p><p>&#x02022; Epithelial defect area</p><p>&#x02022; Schirmer</p><p>&#x02022; TBUT</p></td><td><p>&#x02022; Wound/ocular infection</p><p>&#x02022; Symblepharon</p><p>&#x02022; Corneal vascularization</p></td></tr><tr><td>Lopez-Garcia et al. [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td>2006</td><td>Prospective cohort</td><td>24</td><td>&#x02022; Alkali</td><td><p>&#x02022; Eye surgery</p><p>&#x02022; Eye no surgery</p></td><td>&#x02022; Dua&#x02019;s grade III, IV</td><td>&#x02022; Visual acuity</td><td><p>&#x02022; Corneal ulceration</p><p>&#x02022; Corneal vascularization</p></td></tr><tr><td>Singh et al. [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td>2008</td><td>Retrospective cohort</td><td>100</td><td><p>&#x02022; Acid</p><p>&#x02022; Alkali</p><p>&#x02022; Chemical</p></td><td><p>&#x02022; Eye surgery</p><p>&#x02022; Eye no surgery</p></td><td>&#x02022; Dua&#x02019;s grade II-VI</td><td><p>&#x02022; Visual acuity</p><p>&#x02022; Corneal haze</p></td><td><p>&#x02022; Symblepharon</p><p>&#x02022; Corneal vascularization</p></td></tr><tr><td>Tandon et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td>2011</td><td>Prospective, randomized trial</td><td>153</td><td><p>&#x02022; Thermal</p><p>&#x02022; Acid</p><p>&#x02022; Alkali</p></td><td><p>&#x02022; Eyelid surgery</p><p>&#x02022; Eyelid no surgery</p><p>&#x02022; Eye surgery</p><p>&#x02022; Eye no surgery</p></td><td>&#x02022; Dua&#x02019;s grade II, III</td><td><p>&#x02022; Time to management</p><p>&#x02022; Visual acuity</p><p>&#x02022; Corneal haze</p><p>&#x02022; Epithelial defect area</p><p>&#x02022; Time to epithelialization</p><p>&#x02022; Limbal ischemia</p></td><td><p>&#x02022; Symblepharon</p><p>&#x02022; Corneal vascularization</p></td></tr><tr><td>Sharma et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td>2015</td><td>Retrospective cohort</td><td>28</td><td><p>&#x02022; Acid</p><p>&#x02022; Alkali</p></td><td><p>&#x02022; Eye surgery</p><p>&#x02022; Eye no surgery</p></td><td>&#x02022; Dua&#x02019;s grade III-V</td><td><p>&#x02022; Time to management</p><p>&#x02022; Visual acuity</p><p>&#x02022; Corneal haze</p><p>&#x02022; Epithelial defect diameter</p><p>&#x02022; Epithelial defect area</p><p>&#x02022; Schirmer</p><p>&#x02022; TBUT</p><p>&#x02022; Time to epithelialization</p><p>&#x02022; Healed epithelial defect</p></td><td><p>&#x02022; Symblepharon</p><p>&#x02022; Entropian</p><p>&#x02022; Ectropian</p><p>&#x02022; Corneal vascularization</p></td></tr><tr><td>Sharma et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td>2016</td><td>Prospective, randomized trial</td><td>30</td><td><p>&#x02022; Acid</p><p>&#x02022; Alkali</p></td><td><p>&#x02022; Eye surgery</p><p>&#x02022; Eye no surgery</p></td><td>&#x02022; Dua&#x02019;s grade III-V</td><td><p>&#x02022; Time to management</p><p>&#x02022; Pain</p><p>&#x02022; Corneal haze</p><p>&#x02022; Epithelial defect diameter</p><p>&#x02022; Epithelial defect area</p><p>&#x02022; Schirmer</p><p>&#x02022; TBUT</p><p>&#x02022; Time to epithelialization</p><p>&#x02022; Healed epithelial defect</p><p>&#x02022; Limbal ischemia</p></td><td><p>&#x02022; Symblepharon</p><p>&#x02022; Corneal vascularization</p></td></tr><tr><td>Cabalag et al. [<xref ref-type="bibr" rid="CR2">2</xref>]</td><td>2017</td><td>Retrospective cohort</td><td>326</td><td><p>&#x02022; Thermal</p><p>&#x02022; Chemical</p></td><td><p>&#x02022; Eyelid surgery</p><p>&#x02022; Eyelid no surgery</p><p>&#x02022; Eye surgery</p><p>&#x02022; Eye no surgery</p><p>&#x02022; Eyelash surgery</p><p>&#x02022; Eyelash no surgery</p></td><td><p>&#x02022; SPT</p><p>&#x02022; DPT</p><p>&#x02022; FT</p><p>&#x02022; Dua&#x02019;s grade I, II</p></td><td><p>&#x02022; %TBSA</p><p>&#x02022; Time to management</p><p>&#x02022; LOS</p><p>&#x02022; Rate of intubation</p><p>&#x02022; Inhalation injury</p></td><td><p>&#x02022; Wound/ocular infection</p><p>&#x02022; Eyelid contracture</p><p>&#x02022; Corneal ulceration</p><p>&#x02022; Vision loss</p><p>&#x02022; Ectropian</p></td></tr></tbody></table><table-wrap-foot><p><italic>SPT</italic> superficial partial thickness, <italic>DPT</italic> deep partial thickness, <italic>FT</italic> full thickness, <italic>TBUT</italic> tear break-up time, <italic>LOS</italic> length of stay, <italic>%TBSA</italic> percent total body surface area</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Preferred Reporting Items for Systematic Reviews and Meta-analysis&#x000a0;(PRISMA) flow chart summarizes the results of the screening process and final article selections</p></caption><graphic xlink:href="41038_2019_161_Fig1_HTML" id="MO1"/></fig></p><p id="Par33">The 8 studies included in the systematic review were published from 1983 through 2017. A total of 465 eyes, 253 eyelids, 90 eyelashes, and 0 eyebrows were reported in 271 males and 102 females evaluated within 1&#x000a0;month of burn-related injury. Surgery was performed in 182/465 eyes, 75/253 eyelids, and 15/90 eyelashes. These 272 surgical cases were compared to 535 non-surgical cases. The most reported anatomical structure was the eye (7/8 studies) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], surgical intervention was AMT (5/8 studies) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], outcome was visual acuity on initial evaluation and at follow-up (5/8 studies) [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>], and complication was corneal vascularization at follow-up (6/8 studies) [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. The eyebrow was reported in 0/8 studies. There were three RCTs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], one prospective cohort [<xref ref-type="bibr" rid="CR17">17</xref>], and four retrospective cohort studies [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>], published in English. Five studies were performed in India [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], one in Spain [<xref ref-type="bibr" rid="CR17">17</xref>], one in Australia [<xref ref-type="bibr" rid="CR2">2</xref>], and one in the USA [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par34">Of the 58 possible outcomes and complications queried, 47 had attainable results. The outcomes and complications unable to be found in the context of our literature search were scald burns, contact burns, electrical burns, superficial burns, number of days on a ventilator, ICU LOS, need for reconstruction, time to reconstruction, mortality, keloid/hypertrophic scars, and compression of a neurovascular bundle.</p></sec><sec id="Sec11"><title>Results and risk of bias of individual studies</title><p id="Par35">Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> summarizes each individual study from the 8 articles included in our study. Tables&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref> summarize the details for outcomes and complications of interest assessed for each individual study. All seven risks of bias domains were assessed for each study using the Cochrane risk of bias tool (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Acute surgical and non-surgical management for ocular and peri-ocular burns&#x000a0;study outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Author</th><th rowspan="2">Group</th><th rowspan="2">Sample size (n)</th><th rowspan="2">Surgery</th><th rowspan="2">Time to management (days)</th><th colspan="2">Visual acuity</th><th colspan="2">Pain (0&#x02013;10)</th><th colspan="2">Corneal haze</th><th colspan="2">Epithelial defect diameter (mm)</th><th colspan="2">Epithelial defect area (mm<sup>2</sup>)</th><th rowspan="2">Time to epithelialization&#x000a0;(days)</th><th rowspan="2">Healed epithelial defect</th><th rowspan="2">Schirmer</th><th rowspan="2">TBUT (s)</th><th colspan="2">Limbal ischemia (hours)</th></tr><tr><th>I</th><th>F</th><th>I</th><th>F</th><th>I</th><th>F</th><th>I</th><th>F</th><th>I</th><th>F</th><th>I</th><th>F</th></tr></thead><tbody><tr><td rowspan="3">Frank et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>Surgery</td><td>22</td><td>FTG</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>Surgery</td><td>10</td><td>FTG, T</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>60</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">Tamhane et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td>Surgery</td><td>20</td><td>AMT</td><td>2.5&#x02009;&#x000b1;&#x02009;1</td><td>0.02&#x02009;&#x000b1;&#x02009;0</td><td>0.3&#x02009;&#x000b1;&#x02009;4</td><td>8.8&#x02009;&#x000b1;&#x02009;2</td><td>2.5&#x02009;&#x000b1;&#x02009;0.3</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>97&#x02009;&#x000b1;&#x02009;39</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>7&#x02009;&#x000b1;&#x02009;4</td><td>4&#x02009;&#x000b1;&#x02009;4</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>24</td><td>&#x02013;</td><td>&#x02013;</td><td>0.1&#x02009;&#x000b1;&#x02009;0.2</td><td>0.6&#x02009;&#x000b1;&#x02009;0.4</td><td>8.6&#x02009;&#x000b1;&#x02009;2</td><td>5.5&#x02009;&#x000b1;&#x02009;1</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>61&#x02009;&#x000b1;&#x02009;47</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>8&#x02009;&#x000b1;&#x02009;4</td><td>5&#x02009;&#x000b1;&#x02009;4</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">Lopez-Garcia et al. [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td>Surgery</td><td>12</td><td>AMT</td><td>&#x02013;</td><td>0.2&#x02009;&#x000b1;&#x02009;0.2</td><td>0.63&#x02009;&#x000b1;&#x02009;0.2</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>12</td><td>&#x02013;</td><td>&#x02013;</td><td>0.2&#x02009;&#x000b1;&#x02009;0.2</td><td>0.4&#x02009;&#x000b1;&#x02009;0.2</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">Singh et al. [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td>Surgery</td><td>50</td><td>DALK</td><td>&#x02013;</td><td>0.3&#x02009;&#x000b1;&#x02009;0.6</td><td>0.4&#x02009;&#x000b1;&#x02009;0.2</td><td>&#x02013;</td><td>&#x02013;</td><td>3.7&#x02009;&#x000b1;&#x02009;0.2</td><td>0.2&#x02009;&#x000b1;&#x02009;0.5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>50</td><td>&#x02013;</td><td>&#x02013;</td><td>0.3&#x02009;&#x000b1;&#x02009;0</td><td>0.03&#x02009;&#x000b1;&#x02009;0.5</td><td>&#x02013;</td><td>&#x02013;</td><td>3.7&#x02009;&#x000b1;&#x02009;0.5</td><td>3.6&#x02009;&#x000b1;&#x02009;0.5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="4">Tandon et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td>Surgery</td><td>38</td><td>AMT</td><td>5&#x02009;&#x000b1;&#x02009;12</td><td>0.1&#x02009;&#x000b1;&#x02009;0.3</td><td>0.3&#x02009;&#x000b1;&#x02009;1</td><td>&#x02013;</td><td>&#x02013;</td><td>3&#x02009;&#x000b1;&#x02009;2</td><td>1.3&#x02009;&#x000b1;&#x02009;3</td><td>&#x02013;</td><td>&#x02013;</td><td>47&#x02009;&#x000b1;&#x02009;80</td><td>&#x02013;</td><td>27&#x02009;&#x000b1;&#x02009;52</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>4.5&#x02009;&#x000b1;&#x02009;3</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>36</td><td>&#x02013;</td><td>7&#x02009;&#x000b1;&#x02009;17</td><td>0.04&#x02009;&#x000b1;&#x02009;1</td><td>0.2&#x02009;&#x000b1;&#x02009;0.5</td><td>&#x02013;</td><td>&#x02013;</td><td>2.5&#x02009;&#x000b1;&#x02009;3</td><td>0.5&#x02009;&#x000b1;&#x02009;2</td><td>&#x02013;</td><td>&#x02013;</td><td>48&#x02009;&#x000b1;&#x02009;116</td><td>&#x02013;</td><td>35&#x02009;&#x000b1;&#x02009;69</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>3&#x02009;&#x000b1;&#x02009;4</td><td>&#x02013;</td></tr><tr><td>Surgery</td><td>38</td><td>AMT</td><td>7.5&#x02009;&#x000b1;&#x02009;12</td><td>0.005&#x02009;&#x000b1;&#x02009;0</td><td>0.014&#x02009;&#x000b1;&#x02009;0</td><td>&#x02013;</td><td>&#x02013;</td><td>1.5&#x02009;&#x000b1;&#x02009;3</td><td>2&#x02009;&#x000b1;&#x02009;3</td><td>&#x02013;</td><td>&#x02013;</td><td>114&#x02009;&#x000b1;&#x02009;99</td><td>&#x02013;</td><td>41&#x02009;&#x000b1;&#x02009;65</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>9&#x02009;&#x000b1;&#x02009;4</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>41</td><td>&#x02013;</td><td>7.5&#x02009;&#x000b1;&#x02009;12</td><td>0.01&#x02009;&#x000b1;&#x02009;0</td><td>0.01&#x02009;&#x000b1;&#x02009;0</td><td>&#x02013;</td><td>&#x02013;</td><td>1.3&#x02009;&#x000b1;&#x02009;3</td><td>2.5&#x02009;&#x000b1;&#x02009;3</td><td>&#x02013;</td><td>&#x02013;</td><td>112&#x02009;&#x000b1;&#x02009;106</td><td>&#x02013;</td><td>56&#x02009;&#x000b1;&#x02009;63</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>4.8&#x02009;&#x000b1;&#x02009;4</td><td>&#x02013;</td></tr><tr><td rowspan="2">Sharma et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td>Surgery</td><td>18</td><td>AMT</td><td>7&#x02009;&#x000b1;&#x02009;3</td><td>0.03&#x02009;&#x000b1;&#x02009;0</td><td>0.5&#x02009;&#x000b1;&#x02009;0.4</td><td>&#x02013;</td><td>&#x02013;</td><td>2.3&#x02009;&#x000b1;&#x02009;1</td><td>0.4&#x02009;&#x000b1;&#x02009;1</td><td>7.7&#x02009;&#x000b1;&#x02009;1</td><td>1.7&#x02009;&#x000b1;&#x02009;1</td><td>76&#x02009;&#x000b1;&#x02009;27</td><td>1&#x02009;&#x000b1;&#x02009;2</td><td>41&#x02009;&#x000b1;&#x02009;29</td><td>18</td><td>13.3&#x02009;&#x000b1;&#x02009;2</td><td>9.4&#x02009;&#x000b1;&#x02009;1</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>20</td><td>&#x02013;</td><td>6.6&#x02009;&#x000b1;&#x02009;2</td><td>0.03&#x02009;&#x000b1;&#x02009;0</td><td>0.3&#x02009;&#x000b1;&#x02009;0.3</td><td>&#x02013;</td><td>&#x02013;</td><td>2.4&#x02009;&#x000b1;&#x02009;1</td><td>1&#x02009;&#x000b1;&#x02009;1</td><td>7.2&#x02009;&#x000b1;&#x02009;2</td><td>3.2&#x02009;&#x000b1;&#x02009;2</td><td>54&#x02009;&#x000b1;&#x02009;22</td><td>6&#x02009;&#x000b1;&#x02009;5</td><td>57.8&#x02009;&#x000b1;&#x02009;29</td><td>17</td><td>13.7&#x02009;&#x000b1;&#x02009;1</td><td>8.6&#x02009;&#x000b1;&#x02009;1</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">Sharma et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td>Surgery</td><td>15</td><td>AMT</td><td>4&#x02009;&#x000b1;&#x02009;2</td><td>&#x02013;</td><td>&#x02013;</td><td>6.4&#x02009;&#x000b1;&#x02009;1</td><td>2.4&#x02009;&#x000b1;&#x02009;1</td><td>1.8&#x02009;&#x000b1;&#x02009;1</td><td>1&#x02009;&#x000b1;&#x02009;1</td><td>6&#x02009;&#x000b1;&#x02009;2</td><td>0.2&#x02009;&#x000b1;&#x02009;1</td><td>38&#x02009;&#x000b1;&#x02009;22</td><td>0.4&#x02009;&#x000b1;&#x02009;1</td><td>22&#x02009;&#x000b1;&#x02009;10</td><td>14</td><td>21.2&#x02009;&#x000b1;&#x02009;2</td><td>10.7&#x02009;&#x000b1;&#x02009;2</td><td>7&#x02009;&#x000b1;&#x02009;3</td><td>1.5&#x02009;&#x000b1;&#x02009;2</td></tr><tr><td>No surgery</td><td>15</td><td>&#x02013;</td><td>4.2&#x02009;&#x000b1;&#x02009;1</td><td/><td>&#x02013;</td><td>5.8&#x02009;&#x000b1;&#x02009;1</td><td>2.2&#x02009;&#x000b1;&#x02009;2</td><td>1.7&#x02009;&#x000b1;&#x02009;1</td><td>1.1&#x02009;&#x000b1;&#x02009;1</td><td>5.6&#x02009;&#x000b1;&#x02009;2</td><td>2.6&#x02009;&#x000b1;&#x02009;1</td><td>33&#x02009;&#x000b1;&#x02009;20</td><td>6.8&#x02009;&#x000b1;&#x02009;8</td><td>567&#x02009;&#x000b1;&#x02009;15</td><td>10</td><td>18&#x02009;&#x000b1;&#x02009;4</td><td>10.3&#x02009;&#x000b1;&#x02009;4</td><td>6&#x02009;&#x000b1;&#x02009;3</td><td>3.7&#x02009;&#x000b1;&#x02009;3</td></tr><tr><td rowspan="2">Cabalag et al. [<xref ref-type="bibr" rid="CR2">2</xref>]</td><td>Surgery</td><td>49</td><td>STG, FTG, T</td><td>1&#x02009;&#x000b1;&#x02009;2</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>277</td><td>&#x02013;</td><td>0.6&#x02009;&#x000b1;&#x02009;1</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><p><italic>AMT</italic> amniotic membrane transplantation, <italic>DALK</italic> deep anterior lamellar keratoplasty, <italic>STG</italic> split-thickness graft, <italic>FTG</italic> full-thickness graft, <italic>T</italic> tarsorrhaphy, <italic>I</italic> Initial evaluation, <italic>F</italic> follow-up</p><p>Data presented as mean&#x02009;&#x000b1;&#x02009;standard deviation</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Acute surgical and non-surgical&#x000a0;management for ocular and peri-ocular burns study complications</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Author</th><th rowspan="2">Group</th><th rowspan="2">Sample size (n)</th><th rowspan="2">Surgery</th><th rowspan="2">Wound/ocular infection</th><th rowspan="2">Eyelid contracture</th><th rowspan="2">Corneal ulceration</th><th rowspan="2">Vision loss</th><th colspan="2">Symblepharon</th><th rowspan="2">Entropian</th><th rowspan="2">Ectropian</th><th colspan="2">Corneal vascularization</th><th rowspan="2">Eye perforation</th></tr><tr><th>I</th><th>F</th><th>I</th><th>F</th></tr></thead><tbody><tr><td rowspan="3">Frank et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>Surgery</td><td>22</td><td>FTG</td><td>&#x02013;</td><td>&#x02013;</td><td>7</td><td>1</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>7</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td></tr><tr><td>Surgery</td><td>10</td><td>FTG, T</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>4</td><td>&#x02013;</td><td>&#x02013;</td><td>1</td></tr><tr><td>No surgery</td><td>60</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>4</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td></tr><tr><td rowspan="2">Tamhane et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td>Surgery</td><td>20</td><td>AMT</td><td>1</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>5</td><td>10</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td><td>10</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>24</td><td>&#x02013;</td><td>0</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>4</td><td>12</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>13</td><td>&#x02013;</td></tr><tr><td rowspan="2">Lopez-Garcia et al. [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td>Surgery</td><td>12</td><td>AMT</td><td>&#x02013;</td><td>&#x02013;</td><td>1</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>12</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>4</td><td>&#x02013;</td></tr><tr><td rowspan="2">Singh et al. [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td>Surgery</td><td>50</td><td>DALK</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>1</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>19</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>50</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>31</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>50</td><td>&#x02013;</td></tr><tr><td rowspan="4">Tandon et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td>Surgery</td><td>38</td><td>AMT</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>1</td><td>1</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td><td>15</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>36</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td><td>3</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td><td>25</td><td>&#x02013;</td></tr><tr><td>Surgery</td><td>38</td><td>AMT</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>5</td><td>17</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td><td>25</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>41</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>5</td><td>16</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td><td>25</td><td>&#x02013;</td></tr><tr><td rowspan="2">Sharma et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td>Surgery</td><td>18</td><td>AMT</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>7</td><td>1</td><td>2</td><td>1</td><td>9</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>20</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>12</td><td>2</td><td>2</td><td>2</td><td>13</td><td>&#x02013;</td></tr><tr><td rowspan="2">Sharma et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td>Surgery</td><td>15</td><td>AMT</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>7</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>15</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>10</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>15</td><td>&#x02013;</td></tr><tr><td rowspan="2">Cabalag et al. [<xref ref-type="bibr" rid="CR2">2</xref>]</td><td>Surgery</td><td>49</td><td>STG, FTG, T</td><td>2</td><td>8</td><td>5</td><td>7</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>11</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>No surgery</td><td>277</td><td>&#x02013;</td><td>0</td><td>0</td><td>3</td><td>10</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>0</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><p><italic>AMT</italic> amniotic membrane transplantation, <italic>DALK</italic> deep anterior lamellar keratoplasty, <italic>STG</italic> split-thickness graft, <italic>FTG</italic> full-thickness graft, <italic>T</italic> tarsorrhaphy, <italic>I</italic> initial evaluation, <italic>F</italic> follow-up</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Risk of bias graph and summary: review authors&#x02019; judgments about each risk of bias item for each included study</p></caption><graphic xlink:href="41038_2019_161_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Synthesis of results and risk of bias across studies</title><p id="Par36">The 8 studies included in the systematic review were included in the meta-analysis. Of the 58 possible outcomes and complications queried, 33 were eligible for meta-analysis (Additional&#x000a0;file&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>: Figure S1). Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> summarizes the findings of seven outcomes and complications of interest.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Summary of surgical and non-surgical management for ocular and peri-ocular study findings</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th colspan="2">Illustrative comparative risks<sup>a</sup> (95% CI)</th><th rowspan="3">Relative effect (95% CI)</th><th rowspan="3">No of participants (studies)</th><th rowspan="3">Quality of the evidence (GRADE)</th></tr><tr><th>Assumed risk</th><th>Corresponding risk</th></tr><tr><th>No surgery group</th><th>Surgery group</th></tr></thead><tbody><tr><td>Visual acuity follow-up</td><td>The mean visual acuity on follow-up ranged across control groups from 0.01 to 0.41</td><td>The mean visual acuity on follow-up in the intervention groups was 0.44 higher (0.07 to 0.81 higher)</td><td>SMD 0.44 (0.07 to 0.81)</td><td>262 (4 studies)</td><td><p>&#x02295;&#x02295;&#x0229d;&#x0229d;</p><p>Low<sup>b, c, d, e</sup></p></td></tr><tr><td>Change in epithelial area (mm<sup>2</sup>)</td><td>The mean change in epithelial area ranged across control groups from 26mm<sup>2</sup> to 48mm<sup>2</sup></td><td>The mean change in epithelial area in the intervention groups was 1.37 higher (0.4 to 2.34 higher)</td><td>SMD 1.37 (0.40 to 2.34)</td><td>68 (2 studies)</td><td><p>&#x02295;&#x02295;&#x0229d;&#x0229d;</p><p>Low<sup>b, c, d</sup></p></td></tr><tr><td rowspan="2">Healed epithelial defect</td><td colspan="2">Medium risk population</td><td rowspan="2">RR 1.22 (1.02 to 1.46)</td><td rowspan="2">68 (2 studies)</td><td rowspan="2"><p>&#x02295;&#x02295;&#x0229d;&#x0229d;</p><p>Low<sup>b, c, d</sup></p></td></tr><tr><td>758 per 1000</td><td><p>925 per 1000</p><p>(773 to 1000)</p></td></tr><tr><td rowspan="2">Wound/ocular infection</td><td colspan="2">Medium risk population</td><td rowspan="2">RR 11.17 (1.28 to 597.85)</td><td rowspan="2">173 (2 studies)</td><td rowspan="2"><p>&#x02295;&#x02295;&#x02295;&#x0229d;</p><p>Moderate<sup>b, d</sup></p></td></tr><tr><td>0 per 1000</td><td><p>0 per 1000</p><p>(0 to 0)</p></td></tr><tr><td rowspan="2">Symblepharon follow-up</td><td colspan="2">Medium risk population</td><td rowspan="2">RR 0.55 (0.26 to 1.15)</td><td rowspan="2">312 (5 studies)</td><td rowspan="2"><p>&#x02295;&#x02295;&#x02295;&#x0229d;</p><p>Moderate<sup>c, d</sup></p></td></tr><tr><td>610 per 1000</td><td><p>336 per 1000</p><p>(159 to 701)</p></td></tr><tr><td rowspan="2">Ectropion follow-up</td><td colspan="2">Medium risk population</td><td rowspan="2">RR 7.30 (0.80 to 66.42)</td><td rowspan="2">259 (3 studies)</td><td rowspan="2"><p>&#x02295;&#x02295;&#x0229d;&#x0229d;</p><p>Low<sup>b, c, e</sup></p></td></tr><tr><td>67 per 1000</td><td><p>487 per 1000</p><p>(53 to 1000)</p></td></tr><tr><td rowspan="2">Corneal vascularization follow-up</td><td colspan="2">Medium risk population</td><td rowspan="2">RR 0.64 (0.32 to 1.28)</td><td rowspan="2">336 (6 studies)</td><td rowspan="2"><p>&#x02295;&#x02295;&#x02295;&#x0229d;</p><p>Moderate<sup>b, c</sup></p></td></tr><tr><td>42 per 1000</td><td><p>17 per 1000</p><p>(3 to 105)</p></td></tr></tbody></table><table-wrap-foot><p>Patient or population: ocular, eyelid, eyelash, eyebrow burns</p><p>Settings: inpatient or outpatient</p><p>Intervention: surgery</p><p>Comparison: medical management alone</p><p>GRADE working group grades of evidence</p><p>High quality: further research is very unlikely to change our confidence in the estimate of effect.</p><p>Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</p><p>Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</p><p>Very low quality: we are very uncertain about the estimate.</p><p><italic>CI</italic> Confidence interval, <italic>RR</italic> Risk ratio, <italic>SMD</italic> Standard mean difference</p><p><sup>a</sup>The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p><p><sup>b</sup>Risk of bias</p><p><sup>c</sup>Inconsistency: heterogeneity &#x0003e; 50%</p><p><sup>d</sup>Indirectness: low diversity of patient population</p><p><sup>e</sup>Imprecision: small event size</p><p><sup>f</sup>Publication bias: small study effects</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Surgical intervention</title><p id="Par37">Mean ages ranged from 18 to 41.8&#x02009;years. Studies that reported sex had significantly more males with high heterogeneity (RR 3.32; 95% CI 1.18, 9.35; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;88%; <italic>p</italic>&#x02009;=&#x02009;0.02) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. The most common surgery performed for acute ocular burns was AMT for 115 eyes in 5/8 studies [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], followed by DALK for 50 eyes in 1/8 studies [<xref ref-type="bibr" rid="CR18">18</xref>]. The most common surgery for acute eyelid burns was a full-thickness skin graft for 44 eyelids in 2/8 studies [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], followed by tarsorrhaphy for 16 eyelids in 2/8 studies [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], and split-thickness skin grafts for 3 eyelids in 1/8 studies [<xref ref-type="bibr" rid="CR2">2</xref>]. No surgical interventions were described for the acute management of eyelashes and eyebrows. Direct closure, CLAT, keratolimbal allograft transplantation, penetrating keratoplasty skin substitutes, and tissue flap techniques were not available with our criteria in the literature.</p></sec><sec id="Sec14"><title>Non-surgical intervention</title><p id="Par38">Mean ages ranged from 16 to 40.5&#x02009;years. Studies that reported sex had significantly more males (RR 3.27; 95% CI 1.34, 7.98; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;91%; <italic>p</italic>&#x02009;=&#x02009;0.009) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Medical interventions were provided to all patients for the management of acute burns. Medications included topical medications (corticosteroids prednisolone or dexamethasone, sodium ascorbate, sodium citrate, ethylene diamine tetraacetic acid (EDTA)) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], topical lubricants/irrigation (0.9% NaCl, lactated ringers solution, preservative-free drops) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], topical antimicrobial (oxafloxacin, oxytetracycline, tetracycline, moxifloxacin) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], topical anti-glaucoma (timolol, homatropine, atropine) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], oral medication (vitamin C) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], oral antimicrobial (doxycycline) [<xref ref-type="bibr" rid="CR18">18</xref>], oral anti-glaucoma (acetazolamide) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]).</p></sec><sec id="Sec15"><title>Etiology of burns</title><p id="Par39">Etiologies comprised of 175 thermal burns in 3/8 studies [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], 120 acid burns in 5/8 studies [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], 189 alkali burns in 6/8 studies [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], and 110 uncategorized chemical burns in 2/8 studies [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. No studies compared scald, contact, and electrical burns. Overall, 70% of burns were a result of chemical injury.</p></sec><sec id="Sec16"><title>Classification of burns</title><p id="Par40">The following data for eyelid and eyelash burns was totaled for burn depth: surgery 3 SPT [<xref ref-type="bibr" rid="CR2">2</xref>], 9 DPT [<xref ref-type="bibr" rid="CR2">2</xref>], 5 FT [<xref ref-type="bibr" rid="CR2">2</xref>], 32 DPT/FT [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]; no surgery 60 DPT [<xref ref-type="bibr" rid="CR15">15</xref>]. The following data for ocular burns was totaled after conversion of Roper-Hall to Dua&#x02019;s burn classification: surgery: 17 Grade II [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], 57 Grade III [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], 9 Grade II/III [<xref ref-type="bibr" rid="CR16">16</xref>], 42 Grade IV [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], 18 Grade V [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], 11 Grade VI [<xref ref-type="bibr" rid="CR19">19</xref>], 31 Grade IV/V/VI [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]; No surgery: 17 Grade II [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], 63 Grade III [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>],15 Grade II/III [<xref ref-type="bibr" rid="CR16">16</xref>], 22 Grade IV [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], 14 Grade V [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], 11 Grade VI [<xref ref-type="bibr" rid="CR19">19</xref>], and 29 Grade IV/V/VI [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec17"><title>Time to management</title><p id="Par41">Five studies evaluated the mean time from injury to intervention [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Time to management means ranged from 0.79 to 7.5&#x02009;days in 100 eyes, 43 eyelids, and 15 eyelashes for surgery compared to 0.6 to 7.5&#x02009;days in 197 eyes, 117 eyelids, and 75 eyelashes not having surgery. These results were not significant (SMD 0.01; 95% CI &#x02212;&#x02009;0.25, 0.28; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0%; <italic>p</italic>&#x02009;=&#x02009;0.91).</p></sec><sec id="Sec18"><title>Visual acuity</title><p id="Par42">Four studies evaluated mean visual acuity on initial evaluation and at a designated follow-up time of 3&#x000a0;months [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. Mean initial visual acuity scores ranged from 0.005 to 0.25 in 130 eyes having surgery compared to 0.01 to 0.25 in 132 eyes not having surgery. On the 3-month follow-up, mean visual acuity ranged from 0.014 to 0.6 in eyes having surgery compared to 0.01 to 0.41 in eyes not having surgery. The mean visual acuity on follow-up was 0.44 better for eyes having surgery with medium heterogeneity (SMD 0.44; 95% CI 0.07, 0.81; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;51%; <italic>p</italic>&#x02009;=&#x02009;0.02). After removing as in Singh et al., heterogeneity dropped from medium <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;51% to <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0% and <italic>p</italic>&#x02009;=&#x02009;0.02 to <italic>p</italic>&#x02009;=&#x02009;0.11 [<xref ref-type="bibr" rid="CR18">18</xref>]. The change in visual acuity from baseline ranged from 0.009 to 0.45 in eyes having surgery compared to &#x02212;&#x02009;0.223 to 0.223 in eyes not having surgery. These results were not significant with high heterogeneity (SMD 0.38; 95% CI &#x02212;&#x02009;0.74, 1.50; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;94%; <italic>p</italic>&#x02009;=&#x02009;0.51). No study could be removed to reduce heterogeneity.</p></sec><sec id="Sec19"><title>Pain</title><p id="Par43">Two studies evaluated mean pain scale scores on initial evaluation and at a designated follow-up time of 30&#x02009;days [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Mean initial pain scale scores ranged from 6.4 to 8.8 in 35 eyes having surgery compared to 5.8 to 8.6 in 39 eyes not having surgery. On day 30 follow-ups, mean pain scale scores ranged from 2.4 to 2.5 in eyes having surgery compared to 2.2 to 5.5 in eyes not having surgery. These results were not significant with high heterogeneity (SMD &#x02212;&#x02009;2.3; 95% CI &#x02212;&#x02009;7.13, 2.53; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;98%; <italic>p</italic>&#x02009;=&#x02009;0.35). No study could be removed to assess the high heterogeneity. The mean change in pain from baseline ranged from 4 to 6.3 in eyes having surgery compared to 3.1 to 3.6 in eyes not having surgery over 30&#x02009;days. These results were not significant with high heterogeneity (SMD 1.42, 94% CI &#x02212;&#x02009;0.77, 3.61, <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;94%, <italic>p</italic>&#x02009;=&#x02009;0.20).</p></sec><sec id="Sec20"><title>Corneal haze</title><p id="Par44">Four studies evaluated mean corneal haze grades on initial evaluation and at a designated follow-up time of 3&#x000a0;months for AMT and DALK [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Mean initial corneal haze grades ranged from 1.5 to 3.72 in 133 eyes having surgery compared to 1.25 to 3.7 in 135 eyes not having surgery. On 3-month follow-ups, mean corneal haze grades ranged from 0.195 to 2 in eyes having surgery compared to 0.5 to 3.64 in eyes not having surgery. These results were not significant (SMD 0.06; 95% CI &#x02212;&#x02009;0.18, 0.3; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0%; <italic>p</italic>&#x02009;=&#x02009;0.63). The change in corneal haze from baseline ranged from &#x02212;&#x02009;0.5 to 3.52 in eyes having surgery compared to &#x02212;&#x02009;1.25 to 1.45 in eyes not having surgery. These results were not significant (SMD 0.79; 95% CI &#x02212;&#x02009;0.34, 1.93; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;94%; <italic>p</italic>&#x02009;=&#x02009;0.17). After removing, as in the study by Singh et al. that compared DALK surgery to no surgery, heterogeneity dropped from high <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;94% to <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0% [<xref ref-type="bibr" rid="CR18">18</xref>]. These results were still not significant.</p></sec><sec id="Sec21"><title>Epithelial defect diameter</title><p id="Par45">Two studies evaluated mean epithelial defect diameter on initial evaluation and at a designated follow-up time of 21&#x02009;days [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Mean initial epithelial defect diameters ranged from 6.4 to 7.74&#x02009;mm in 33 eyes having surgery compared to 5.6 to 7.19&#x02009;mm in 35 eyes not having surgery. On day 21 follow-ups, mean epithelial defect diameters ranged from 0.2 to 1.73&#x02009;mm in eyes having surgery compared to 2.6 to 3.21&#x02009;mm in eyes not having surgery. The mean epithelial defect diameter was 1.63&#x02009;mm smaller for eyes having AMT surgery on follow-up with high heterogeneity (SMD &#x02212;&#x02009;1.63; 95% CI &#x02212;&#x02009;2.87, &#x02212;&#x02009;0.38; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;78%; <italic>p</italic>&#x02009;=&#x02009;0.01). No study could be removed to assess the high heterogeneity. The change in epithelial defect diameter from baseline ranged from 5.8 to 6 in eyes having surgery compared to 3 to 3.98 in eyes not having surgery. The change in mean epithelial defect diameter was 1.55&#x02009;mm greater for eyes having AMT surgery (SMD 1.55; 95% CI 1, 2.1; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.00001).</p></sec><sec id="Sec22"><title>Epithelial defect area</title><p id="Par46">Four studies evaluated mean epithelial defect area on initial evaluation [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. In two studies, mean epithelial defect area was measured at initial evaluation and designated follow-up time of 21&#x02009;days [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Mean initial epithelial defect areas ranged from 37.9 to 76.13mm<sup>2</sup> in 33 eyes having surgery compared to 32.6 to 53.88mm<sup>2</sup> in 35 eyes not having surgery. On day 21 follow-ups, mean epithelial defect areas ranged from 0.4 to 1.1mm<sup>2</sup> in eyes having surgery compared to 6.01 to 6.8mm<sup>2</sup> in eyes not having surgery. The mean epithelial defect area was 1.17mm<sup>2</sup> smaller for eyes having AMT surgery on follow-up (SMD &#x02212;&#x02009;1.17; 95% CI &#x02212;&#x02009;1.69, &#x02212;&#x02009;0.65; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). The change in epithelial defect area from baseline ranged from 37.5 to 75 in eyes having surgery compared to 25.8 to 47.87 in eyes not having surgery. The change in mean epithelial defect area was 1.37mm<sup>2</sup> greater for eyes having AMT surgery (SMD 1.37; 95% CI 0.4, 2.34; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;69%; <italic>p</italic>&#x02009;=&#x02009;0.006).</p></sec><sec id="Sec23"><title>Tear film status</title><p id="Par47">Three studies evaluated tear film status 3&#x000a0;months following management using the Schirmer test and TBUT at 3&#x000a0;months follow-up [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Mean Schirmer tests ranged from 6.88 to 21.2&#x02009;mm of moisture in 53 eyes having AMT surgery compared to 8.13 to 18&#x02009;mm of moisture in 59 eyes not having surgery. These results were not significant (SMD 0.07; 95% CI &#x02212;&#x02009;0.72, 0.86; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;76%, <italic>p</italic>&#x02009;=&#x02009;0.86). After removing the RCT study by Sharma et al., heterogeneity dropped from high <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;76% to <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0% [<xref ref-type="bibr" rid="CR21">21</xref>]. These results were still not significant. Mean TBUT ranged from 4.18 to 10.7&#x02009;s in 53 eyes having AMT surgery compared to 5.09 to 10.3&#x02009;s in 59 eyes not having surgery. These results were not significant (SMD 0.22; 95% CI &#x02212;&#x02009;0.4, 0.84; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;63%; <italic>p</italic>&#x02009;=&#x02009;0.49). After removing the retrospective study by Sharma et al., heterogeneity dropped from <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;63% to <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0% [<xref ref-type="bibr" rid="CR20">20</xref>]. These results were still not significant.</p></sec><sec id="Sec24"><title>Time to epithelialization</title><p id="Par48">Three studies evaluated time to epithelialization [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Mean time to epithelialization ranged from 22 to 41.13&#x02009;days in 83 eyes having AMT surgery compared to 35 to 57.75&#x02009;days in 85 eyes not having surgery. These results were not significant with high heterogeneity (SMD &#x02212;&#x02009;0.8; 95% CI &#x02212;&#x02009;1.65, 0.05; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;85%; <italic>p</italic>&#x02009;=&#x02009;0.07). After removing the RCT study by Sharma et al., heterogeneity dropped from high <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;85% to <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0% [<xref ref-type="bibr" rid="CR21">21</xref>]. These results were still not significant.</p></sec><sec id="Sec25"><title>Healed epithelial defect</title><p id="Par49">Two studies evaluated the number of fully healed epithelial defects 3&#x000a0;months following management [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The defects healed in 32/33 (97%) eyes having AMT surgery compared to 27/35 (77%) eyes not having surgery (RR 1.22; 95% CI 1.02, 1.46; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0%; <italic>p</italic>&#x02009;=&#x02009;0.03).</p></sec><sec id="Sec26"><title>Limbal ischemia</title><p id="Par50">Two studies evaluated limbal ischemia on initial evaluation [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and one study at a designated follow-up time of 3&#x000a0;months with acid and alkali burns involving 30 eyes [<xref ref-type="bibr" rid="CR21">21</xref>]. Limbal ischemia means on initial evaluation ranged from 4.5 to 9.25 clock hours in eyes having surgery compared to 2.75 to 5.8 clock hours in eyes not having surgery with high heterogeneity (SMD 0.69; 95% CI &#x02212;&#x02009;0.32, 1.71; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;87%; <italic>p</italic>&#x02009;=&#x02009;0.18). No study could be removed to assess the high heterogeneity. One study reported on three-month follow-ups, limbal ischemia means were 1.5 clock hours in 15 eyes having AMT surgery compared to 3.7 clock hours in 15 eyes not having surgery (<italic>p</italic>&#x02009;=&#x02009;0.015) [<xref ref-type="bibr" rid="CR21">21</xref>]. No study could be removed to assess the high heterogeneity.</p></sec><sec id="Sec27"><title>Wound/ocular infections</title><p id="Par51">Two studies evaluated the occurrence of a local infection with burns to the eyes, eyelids, and eyelashes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Ocular keratitis occurred in 3/37 (8%) eyes having surgery compared to 0/136 (0%) eyes not having surgery (RR 11.17; 95% CI 1.28, 97.85; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0%; <italic>p</italic>&#x02009;=&#x02009;0.03). In one case following AMT, keratitis was caused by coagulase-negative <italic>Staphylococus</italic> [<xref ref-type="bibr" rid="CR16">16</xref>]<italic>.</italic> The other two cases followed a combination of split-thickness skin grafts, full-thickness skin grafts, and/or tarsorrhaphies [<xref ref-type="bibr" rid="CR2">2</xref>].</p></sec><sec id="Sec28"><title>Corneal ulceration</title><p id="Par52">Three studies evaluated the occurrence of corneal ulceration from 6 to 9&#x000a0;months follow-up after burns involving the eyes, eyelids, and eyelashes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Ulceration occurred in 13/61 (21%) eyes having surgery compared to 13/184 (7%) eyes not having surgery (RR 2.04; 95% CI 0.29, 14.62; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;83%; <italic>p</italic>&#x02009;=&#x02009;0.48). Surgeries performed were AMT, split-thickness skin grafts, full-thickness skin grafts, and/or tarsorrhaphies. After removing the prospective AMT study by Lopez-Garcia et al., heterogeneity dropped from high <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;83% to medium <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;63% (RR 5.06; 95% CI 1.24, 20.73; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;63%; <italic>p</italic>&#x02009;=&#x02009;0.02) [<xref ref-type="bibr" rid="CR17">17</xref>]. Split-thickness skin grafts, full-thickness skin grafts, and/or tarsorrhaphies were more likely to result in corneal ulceration.</p></sec><sec id="Sec29"><title>Vision loss</title><p id="Par53">Two studies evaluated the occurrence of vision loss with burns to the eyes, eyelids, and eyelashes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Vision loss occurred in 8/49 (16%) eyes having surgery compared to 10/172 (6%) eyes not having surgery (RR 4.67; 95% CI 2.11, 10.32; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;0%; <italic>p</italic>&#x02009;=&#x02009;0.0001). Surgeries included split-thickness skin grafts, full-thickness skin grafts, and tarsorrhaphies [<xref ref-type="bibr" rid="CR2">2</xref>]. In the study by Cabalag et al., vision loss was the most common late complication as a result of flame or explosion burns [<xref ref-type="bibr" rid="CR2">2</xref>]. Surgery was performed in patients with a combination of more severe eyelid burns that were FT and corneal injury than those not having surgery. In the study by Frank et al., vision loss occurred in one patient as a result of the original injury [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec30"><title>Symblepharon</title><p id="Par54">Two studies evaluated the occurrence of symblepharon on initial evaluation [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] and five studies at a designated follow-up time of 3&#x000a0;months with burns involving the eyes and eyelids [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Symblepharon on initial evaluation occurred in 11/70 (16%) eyes having surgery compared to 9/74 (12%) eyes not having surgery. On 3-month follow-ups, symblepharon occurred in 41/153 (27%) eyes having surgery DALK and AMT compared to 84/159 (53%) eyes not having surgery. These results were not significant (RR 0.55; 95% CI 0.26, 1.15; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;81%; <italic>p</italic>&#x02009;=&#x02009;0.11). After removing the DALK surgery as in study by Singh et al., heterogeneity dropped from high <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;81% to low <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;16%. These results were still not significant.</p></sec><sec id="Sec31"><title>Ectropian</title><p id="Par55">Three studies evaluated the occurrence of ectropian from 3 to 6-months follow-up after burns involving the eyes, eyelids, and eyelashes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Ectropian occurred in 24/67 (36%) having surgery compared to 6/192 (3%) not having surgery (RR 7.3; 95% CI 0.8, 66.42; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;78%, <italic>p</italic>&#x02009;=&#x02009;0.08). After removing the study by Cabalag et al., heterogeneity dropped from high <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;78% to medium <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;50% [<xref ref-type="bibr" rid="CR2">2</xref>]. These results were still not significant. Surgery was performed in patients with a combination of more severe eyelid burns that were FT and corneal injury than those not having surgery.</p></sec><sec id="Sec32"><title>Corneal vascularization</title><p id="Par56">Three studies evaluated corneal vascularization on initial evaluation [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] and six studies at a designated follow-up time of 3&#x000a0;months, after burns involving the eyes and eyelids [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Corneal vascularization occurred at initial evaluation in 1/88 (1%) eyes having surgery compared to 4/94 (4%) eyes not having surgery. On 3-month follow-ups, corneal vascularization occurred in 87/165 (53%) eyes having surgery compared to 145/171 (85%) eyes not having surgery. These results were not significant (RR 0.64; 95% CI 0.32, 1.28; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;96%, <italic>p</italic>&#x02009;=&#x02009;0.21). After removing the RCT study by Tandon et al., heterogeneity dropped from high <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;96% to medium <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;53% (RR 0.57; 95% CI 0.39, 0.83; <italic>I</italic><sup>2</sup>&#x000a0;=&#x02009;50%; <italic>p</italic>&#x02009;=&#x02009;0.004) [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec></sec><sec id="Sec33"><title>Discussion</title><p id="Par57">This was the first systematic review and meta-analysis comparing studies with surgical to non-surgical interventions for the management of ocular, eyelid, eyelash, and/or eyebrow burns in the acute phase of treatment. Patients having surgery were found to have greater visual acuity on follow-up, shorter epithelial defect diameters on follow-up, greater changes in epithelial diameters from baseline, smaller epithelial defect areas on follow-up, greater changes in epithelial defect areas from baseline, greater numbers of healed epithelial defects, more keratitis infections, and a greater reduction in limbal ischemia, possibility preventing the need of a future limbal stem cell transplantation. Vision loss was higher in the surgical intervention group; however, vision loss on initial evaluation and more severe burns were present in this group.</p><p id="Par58">Our results from analyses displayed in Additional&#x000a0;file&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>: Figure S1 demonstrate the distribution of available data for acute surgical and non-surgical outcomes related to ocular burns. Our findings revealed no differences between thermal, acid, alkali, and uncategorized chemical burns. The majority of included patients suffered from alkali burns. There were no differences in pain scores; however, Tamhane et al. found significantly greater reductions in discomfort scores day 1 with moderate burns and day 14 with severe burns following AMT compared to their control group. Surgical interventions were associated with reducing pain during the acute phase [<xref ref-type="bibr" rid="CR16">16</xref>]. Vision loss was higher in the surgical group and not included in our report due to the unequal groups of higher severities of burns and vision loss prior to management. We believed these results incorrectly influenced the interpretation of data [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. No differences were seen with time to management, changes in visual acuity, corneal haze, Schirmer and TBUT tests, time to epithelialization, corneal ulceration, symblepharon, and corneal vascularization. Initial surgical management is a reasonable option for Dua&#x02019;s Grade II to VI ocular burns. Surgery has a higher risk of ocular infections. This risk may be outweighed by the benefit of greater visual acuity at long-term follow-up and reduced defect sizes.</p><p id="Par59">Limitations existed with our study findings. Studies that included surgical and non-surgical interventions were a mix of RCTs and retrospectively performed studies, primarily performed in India. Combining RCTs, the prospective cohort, and retrospective cohorts were performed in compliance with methods outlined by the Cochrane Collaboration to include all relevant data from the literature. There results provide little evidence for effect size estimate differences between observational studies and RCTs, regardless of specific observational study design, heterogeneity, inclusion of pharmacological studies, or use of propensity score adjustment [<xref ref-type="bibr" rid="CR22">22</xref>]. We included patients with a mean age &#x02265;&#x02009;15&#x02009;years to account for studies that reported only means. This age cutoff was chosen on the basis of varying definitions for adult patients from starting ages 15 to 21 within the literature and to maintain a comprehensive review [<xref ref-type="bibr" rid="CR23">23</xref>]. Only eight studies were available for comparison, limiting the ability to use funnel plots for assessing study heterogeneity. Therefore, sensitivity analysis was best performed using single study elimination to identify which study contributed the most heterogeneity. Sensitivity analysis was not mentioned for all outcomes if the initial results were not significant, and the analysis did not significantly contribute to a change in statistical significance. Studies were inconsistent with reporting the involvement of anatomical subunits surrounding the eye following ocular burns and the eye itself following eyelid burns. Criteria for determining grades of corneal injury varied between Roper-Hall and Dua&#x02019;s classifications. Experts often have different opinions on grade severity within the same classification for corneal injury. Many tests including limbal ischemia are subjective and depend on clinical interpretation. Corneal clarity and corneal haze were inconsistently used. We attempted to unify the data by converting corneal clarity to corneal haze. Although the majorities of studies were performed in India and had a higher proportion of male participants, the highest level of care was provided to all study participants. As long as medical facilities are equipped with standard resources, the results may be generalizable to other populations. Study dates ranged from 1983 through 2017, a 34-year time period with many gaps throughout the timeline. Our search revealed a lack of data reported within the literature. Outcomes and complications with no identifiable information included scald burns, contact burns, electrical burns, superficial burns, number of days on a ventilator, ICU LOS, need for reconstruction, time to reconstruction, mortality, keloid/hypertrophic scars, and compression of a neurovascular bundle. Outcomes and complications were unavailable for meta-analysis due to single reports were %TBSA, Dua&#x02019;s grade I burns, Dua&#x02019;s grade VI burns, limbial ischemia on follow-up, limbal ischemia changes from baseline, hospital LOS, intubation rate, inhalation injury, eyelid contracture, and entropian on follow-up. Only one study reported the cultured organism following keratitis. This may result in the inability of the surgeon to determine the best management during the acute phase for the best outcomes in the chronic phase of reconstruction. The small sample volume for comparison may explain the high risks of selection bias and unclear bias, and large degrees of heterogeneity observed across studies following meta-analysis. We used the random effects model in all outcomes to reduce the risk of bias in individual studies and across studies. To maintain the highest level of consistency and minimize heterogeneity, the authors applied this method for all results. Many studies could not be included due to no comparative groups or single cases. Sample demographics lacked comorbidities, limiting the ability to assess the influence of confounding patient variables on outcomes and complications.</p><p id="Par60">These limitations demonstrate why it was important to perform this systematic review and meta-analysis. By conducting this never performed systematic review and meta-analysis, we identified future areas of research that can contribute a wealth of knowledge to the literature for healthcare providers and patients. In addition, we compared the differences in outcomes and complications across studies with the highest level of evidence available.</p></sec><sec id="Sec34"><title>Conclusion</title><p id="Par61">Patients having surgery for ocular, eyelid, and/or eyelash burns were found to have greater visual acuity on follow-up, shorter epithelial defect diameters on follow-up, greater changes in epithelial diameters from baseline, smaller epithelial defect areas on follow-up, greater changes in epithelial defect areas from baseline, greater numbers of healed epithelial defects, more keratitis infections, and a greater reduction in limbal ischemia, possibility preventing the need of a future limbal stem cell transplantation.</p></sec><sec sec-type="supplementary-material"><title>Additional file</title><sec id="Sec35"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41038_2019_161_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p>Search Strategies. (DOCX 111 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41038_2019_161_MOESM2_ESM.docx"><label>Additional file 2:</label><caption><p><bold>Figure S1.</bold> Forest plots with comparisons of outcomes and complications in meta-analysis. (DOCX 19982 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>%TBSA</term><def><p id="Par5">Percent total body surface area</p></def></def-item><def-item><term>AMT</term><def><p id="Par6">Amniotic membrane transplant</p></def></def-item><def-item><term>CI</term><def><p id="Par7">Confidence intervals</p></def></def-item><def-item><term>CLAT</term><def><p id="Par8">Conjunctival limbal autograft transplantation</p></def></def-item><def-item><term>DALK</term><def><p id="Par9">Deep anterior lamellar keratoplasty</p></def></def-item><def-item><term>DPT</term><def><p id="Par10">Deep partial thickness</p></def></def-item><def-item><term>FT</term><def><p id="Par11">Full thickness</p></def></def-item><def-item><term>ICU</term><def><p id="Par13">Intensive care unit</p></def></def-item><def-item><term>LOS</term><def><p id="Par14">Length of stay</p></def></def-item><def-item><term>RCT</term><def><p id="Par15">Randomized controlled trial</p></def></def-item><def-item><term>RR</term><def><p id="Par16">Risk ratios</p></def></def-item><def-item><term>S</term><def><p id="Par17">Superficial</p></def></def-item><def-item><term>SMD</term><def><p id="Par18">Standard mean differences</p></def></def-item><def-item><term>SPT</term><def><p id="Par19">Superficial partial thickness</p></def></def-item><def-item><term>TBUT</term><def><p id="Par20">Tear break-up time</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We thank Carrie Cox, MS, RN and Vidhi Javia, BS, for their assistance with coordinating clinical research at The Johns Hopkins Burn Center. Meredith Klifto, MD for her exceptional knowledge and council as an ophthalmologist. Without their assistance, our work would not be possible.</p><sec id="FPar1"><title>Funding</title><p id="Par62">This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></sec><sec id="FPar2" sec-type="data-availability"><title>Availability of data and materials</title><p id="Par63">The data used and/or analyzed during the current study are accessible online.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>The authors KMK, AE, CFG, SMS, MA, and CSH all contributed equally to the conception and design, acquisition of the data, or analysis and interpretation of the data. KMK drafted the manuscript. MA and CSH revised it critically for important intellectual content. All authors KMK, AE, CFG, SMS, MA, and CSH approved the final manuscript version to be published. All authors KMK, AE, CFG, SMS, MA, and CSH agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par64">This study was exempt from institutional review board approval.</p></notes><notes><title>Consent for publication</title><p id="Par65">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par66">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Burn Association</collab></person-group><source>Burn Center Referral Criteria</source><year>2006</year></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabalag</surname><given-names>MS</given-names></name><name><surname>Wasiak</surname><given-names>J</given-names></name><name><surname>Syed</surname><given-names>Q</given-names></name><name><surname>Paul</surname><given-names>E</given-names></name><name><surname>Hall</surname><given-names>AJ</given-names></name><name><surname>Cleland</surname><given-names>H</given-names></name></person-group><article-title>Risk factors for ocular burn injuries requiring surgery</article-title><source>J Burn Care Res</source><year>2017</year><volume>38</volume><issue>2</issue><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1097/BCR.0000000000000390</pub-id><pub-id pub-id-type="pmid">27355655</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SB</given-names></name><name><surname>Coffee</surname><given-names>T</given-names></name><name><surname>Yowler</surname><given-names>C</given-names></name><name><surname>Steinemann</surname><given-names>TL</given-names></name></person-group><article-title>Risk factors for ophthalmic complications in patients with burns</article-title><source>J Burn Care Res</source><year>2010</year><volume>31</volume><issue>6</issue><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1097/BCR.0b013e3181f93712</pub-id><pub-id pub-id-type="pmid">20859213</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Hall</surname><given-names>AJ</given-names></name><name><surname>Stawell</surname><given-names>RJ</given-names></name></person-group><article-title>Ophthalmologic sequelae of thermal burns over ten years at the Alfred Hospital</article-title><source>Ophthalmic Plast Reconstr Surg</source><year>2002</year><volume>18</volume><issue>3</issue><fpage>196</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1097/00002341-200205000-00008</pub-id><pub-id pub-id-type="pmid">12021650</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Mulrow</surname><given-names>C</given-names></name><name><surname>Gotzsche</surname><given-names>PC</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><etal/></person-group><article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</article-title><source>PLoS Med</source><year>2009</year><volume>6</volume><issue>7</issue><fpage>e1000100</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000100</pub-id><pub-id pub-id-type="pmid">19621070</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dua</surname><given-names>HS</given-names></name><name><surname>King</surname><given-names>AJ</given-names></name><name><surname>Joseph</surname><given-names>A</given-names></name></person-group><article-title>A new classification of ocular surface burns</article-title><source>Br J Ophthalmol</source><year>2001</year><volume>85</volume><issue>11</issue><fpage>1379</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1136/bjo.85.11.1379</pub-id><pub-id pub-id-type="pmid">11673310</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roper-Hall</surname><given-names>MJ</given-names></name></person-group><article-title>Thermal and chemical burns</article-title><source>Trans Ophthalmol Soc U K</source><year>1965</year><volume>85</volume><fpage>631</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">5227208</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savovic</surname><given-names>J</given-names></name><name><surname>Weeks</surname><given-names>L</given-names></name><name><surname>Sterne</surname><given-names>JA</given-names></name><name><surname>Turner</surname><given-names>L</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><etal/></person-group><article-title>Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation</article-title><source>Syst Rev</source><year>2014</year><volume>3</volume><fpage>37</fpage><lpage>4053-3-37</lpage><pub-id pub-id-type="doi">10.1186/2046-4053-3-37</pub-id><pub-id pub-id-type="pmid">24731537</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">American Society of Cataract and Refractive Surgery and European Society of Cataract and Refractive Surgeons. Visual acuity conversion chart. J Cataract Refract Surg. 2004;30(9).</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Kalaivani</surname><given-names>M</given-names></name><name><surname>Tandon</surname><given-names>R</given-names></name></person-group><article-title>Comparison of prognostic value of Roper Hall and Dua classification systems in acute ocular burns</article-title><source>Br J Ophthalmol</source><year>2011</year><volume>95</volume><issue>2</issue><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1136/bjo.2009.173724</pub-id><pub-id pub-id-type="pmid">20805137</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>T</given-names></name></person-group><article-title>Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range</article-title><source>BMC Med Res Methodol</source><year>2014</year><volume>14</volume><fpage>135</fpage><lpage>2288-14-135</lpage><pub-id pub-id-type="doi">10.1186/1471-2288-14-135</pub-id><pub-id pub-id-type="pmid">25524443</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmid">12958120</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>MS</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Woolacott</surname><given-names>NF</given-names></name></person-group><article-title>Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool</article-title><source>Res Synth Methods</source><year>2014</year><volume>5</volume><issue>1</issue><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1002/jrsm.1090</pub-id><pub-id pub-id-type="pmid">26054027</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011:Available from <ext-link ext-link-type="uri" xlink:href="https://training.cochrane.org/handbook">https://training.cochrane.org/handbook</ext-link>. Accessed 3 June 2019.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>DH</given-names></name><name><surname>Wachtel</surname><given-names>T</given-names></name><name><surname>Frank</surname><given-names>HA</given-names></name></person-group><article-title>The early treatment and reconstruction of eyelid burns</article-title><source>J Trauma</source><year>1983</year><volume>23</volume><issue>10</issue><fpage>874</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1097/00005373-198310000-00005</pub-id><pub-id pub-id-type="pmid">6355497</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamhane</surname><given-names>A</given-names></name><name><surname>Vajpayee</surname><given-names>RB</given-names></name><name><surname>Biswas</surname><given-names>NR</given-names></name><name><surname>Pandey</surname><given-names>RM</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Titiyal</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><issue>11</issue><fpage>1963</fpage><lpage>1969</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2005.05.022</pub-id><pub-id pub-id-type="pmid">16198422</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Garcia</surname><given-names>JS</given-names></name><name><surname>Rivas</surname><given-names>L</given-names></name><name><surname>Garcia-Lozano</surname><given-names>I</given-names></name><name><surname>Murube</surname><given-names>J</given-names></name></person-group><article-title>Analysis of corneal surface evolution after moderate alkaline burns by using impression cytology</article-title><source>Cornea</source><year>2006</year><volume>25</volume><issue>8</issue><fpage>908</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1097/01.ico.0000225711.54888.e8</pub-id><pub-id pub-id-type="pmid">17102665</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Singh Bhinder</surname><given-names>H</given-names></name></person-group><article-title>Evaluation of therapeutic deep anterior lamellar keratoplasty in acute ocular chemical burns</article-title><source>Eur J Ophthalmol</source><year>2008</year><volume>18</volume><issue>4</issue><fpage>517</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1177/112067210801800403</pub-id><pub-id pub-id-type="pmid">18609468</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandon</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Kalaivani</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Titiyal</surname><given-names>JS</given-names></name><name><surname>Vajpayee</surname><given-names>RB</given-names></name></person-group><article-title>Amniotic membrane transplantation as an adjunct to medical therapy in acute ocular burns</article-title><source>Br J Ophthalmol</source><year>2011</year><volume>95</volume><issue>2</issue><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1136/bjo.2009.173716</pub-id><pub-id pub-id-type="pmid">20675729</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Lathi</surname><given-names>SS</given-names></name><name><surname>Sehra</surname><given-names>SV</given-names></name><name><surname>Agarwal</surname><given-names>T</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Titiyal</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Comparison of umbilical cord serum and amniotic membrane transplantation in acute ocular chemical burns</article-title><source>Br J Ophthalmol</source><year>2015</year><volume>99</volume><issue>5</issue><fpage>669</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2014-305760</pub-id><pub-id pub-id-type="pmid">25370084</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Maharana</surname><given-names>PK</given-names></name><name><surname>Kriplani</surname><given-names>A</given-names></name><name><surname>Velpandian</surname><given-names>T</given-names></name><name><surname>Pandey</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Comparison of amniotic membrane transplantation and umbilical cord serum in acute ocular chemical burns: a randomized controlled trial</article-title><source>Am J Ophthalmol</source><year>2016</year><volume>168</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2016.05.010</pub-id><pub-id pub-id-type="pmid">27210276</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database of Systematic Reviews. 2014;(4). Art. No.MR000034. 10.1002/14651858.MR000034.pub2.</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Romanowski KS, Palmieri TL. Pediatric burn resuscitation: past, present, and future. Burns Trauma. 2017;5:26.</mixed-citation></ref></ref-list></back></article>